Long-term follow-up of 46 consecutive BMT patients who received recombinant human macrophage colony-stimulating factor (rhM-CSF) as adjunctive therapy with standard antifungal treatment who were entered into phase 1/11 trials at The Fred Hutchinson Cancer Research Center is reported. rhM-CSF (100 gg/mz to 2,000 pg/m2; Chiron/ Cetus Corporation, Emeryville, CA) was administered from day 0 to 28 after determination of progressive fungal disease. Results of long-term follow-up of fungal infection, relapse, and survival were compared with 58 similar his-EN PERCENT of patients undergoing allogeneic bone T marrow transplantation (BMT) will develop invasive fungal disease with an associated high morbidity and mortalit^.'*^ Prophylactic treatment with antifungal agents or use of laminar air flow rooms may reduce the incidence of fungal infection4%'; however, once infection develops, little therapy other than treatment with amphotericin is available.
T marrow transplantation (BMT) will develop invasive fungal disease with an associated high morbidity and mortalit^.'*^ Prophylactic treatment with antifungal agents or use of laminar air flow rooms may reduce the incidence of fungal infection4%'; however, once infection develops, little therapy other than treatment with amphotericin is available.
Recombinant human macrophage colony-stimulating factor (rhM-CSF) is a cytokine that stimulates the survival, proliferation, and differentiation and enhances the function of monocytes and macrophage^.^.' Preclinical studies show that this activity is associated with a substantial increase in the ability of monocytes and macrophages to kill fungi.' rhM-CSF was well tolerated when administered to patients who developed invasive fungal infection after BMT' and in patients with metastatic cancer." Other than thrombocytopenia, which was a dose-limiting toxicity, no other significant side effects were observed. Several patients had resolution of fungal infection contemporaneously with rhM-CSF and amphotericin treatment'; however, long-term assessments were not performed. This article reports long-term follow-up of the 24 rhM-CSF-treated patients who were originally reported in addition to 22 consecutive patients who received rhM-CSF at the maximum tolerated dose of 2,000 pg/m2/d. torical controls. Multivariable analysis of the patients who received rhM-CSF showed two factors that significantly correlated with poor survival: Karnofsky score s 20% and Aspergillus infection. Overall, survival of patients who received rhM-CSF was greater than that of historical patients (27% v 5%) and was entirely because of a 50% survival rate in patients with Candida infection and Karnofsky scores greater than 20%. Prospective, randomized, controlled trials to determine efficiency of rhM-CSF are indicated and should be directed at patients with invasive candidiasis.
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MATERIALS AND METHODS

Patient selection.
Patients with presumed or documented fungal infections before or after BMT were eligible. No exclusions were made for diagnosis, age, graft-versus-host disease (GVHD) status or Kamofsky performance scores. Results of the first 24 patients have been previously published.' Subsequently, an additional 22 consecutive patients who received rhM-CSF at 2,000 pg/m2/d were entered into trial. Clinical characteristics of the 46 patients who received rhM-CSF are shown in Table 1 . Informed consent conforming to Federal Drug Administration and Institutional Review Board Guidelines was required. Comparison of study patients was made to historical control patients. A summary of the characteristics of both patient groups is shown in Table 2 .
Patients were included if they had one of the following characteristics: documented invasive fungal infection demonstrated by histologic analysis or cultures of closed-body fluids or tissue biopsies, a single, positive blood culture with radiologic evidence of invasive disease, two or more positive blood cultures for Candida species without a documented local site of infection, or persistent fever with fungi dated from bronchial alveolar lavage fluid with radiologic studies suggestive of fungal infection.
All patients were examined daily while receiving rhM-CSF. Bone marrow aspirates and biopsies were performed before therapy to rule out malignancy. Blood cultures were taken as clinically indicated. Chemistries and complete blood cell counts were performed daily. Evaluation of fungal infection was performed by repeating the initial diagnostic procedure when possible or at autopsy. Long-term follow-up, evaluation for the persistence of fungal infection, cause of death, and survival was made by review of medical records and phone conversations with the patient's primary physician. Diagnostic procedures originally used to document fungal infection were repeated when possible or at autopsy.
The design of the study into which the initial 24 patients were entered has been previously described? The subsequent 22 patients received rhM-CSF at a dose of 2,000 pg/m2/d by 2-hour intravenous infusion for 28 consecutive days. rhM-CSF (specific activity: 1 X 10' U/mg; Cetus Corporation, Emeryville, CA) was administered in 100 mL of normal saline with 0.25% albumin by central venous catheter. All patients received amphotericin at maximally tolerated doses (.5 to 1.0 pg/kg/d). Results were compared with 58 historical patients who were retrospectively identified 
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RESULTS
Thrombocytopenia (reduction by more than 50%) was observed in 9 of the first 24 patients who received rhM-CSF. Thrombocytopenia occurred in 2 of the subsequent 22 patients (UPNs 5074, 5929) and both required a dose reduction of 50% (to 1,000 pg/m2/d). Platelet counts remained low until rhM-CSF was discontinued; however, platelet counts did not decrease further after institution of the lower rhM-CSF dose. No other toxicity ascribed to rhM-CSF was observed.
Presence of fungal infection at day of follow-up evaluation. Twelve (87%) patients who did not survive 15 days had evidence of persistent fungal infection at the time of death (Tables 1 and 3) . Patients who survived and received more than 2 weeks of therapy with rhM-CSF had a low incidence of fungal infection at time offollow-up (5/30, 17%). No patients who survived more than 150 days had documentation of recurrent fungal infection.
Survival. Cox regression using survival time in days as the outcome variable showed two significant independent predictor variables: Kamofsky performance scores 5 20% ( P < .001; odds ratio = 6.97) and type of fungus (Aspergillus) ( P = .055; odds ratio = 2.01) that were associated with lower survival. The logistic regression using evaluation of the presence of fungus at time of follow-up evaluation (present or not present) as the outcome variable also showed the same two significant predictors: Karnofsky performance scores of 120% ( P < .OO 1, odds ratio = 37.94) and Aspergillus infection ( P = .OO 1, odds ratio = 2 1.69). Survival of all patients who received rhM-CSF compared with historical controls is shown in Fig 1. Median follow-up of surviving patients who received rhM-CSF was 642 days (range 370 days to 903 days). Twelve patients remain alive and free of fungal disease. Thirty-four patients did not survive. The incidence of recurrence of malignancy was similar in the rhM-CSF-treated patients and the historical patients. Causes of death are shown in Table 1 . The difference in overall survival was entirely because of better survival of patients with >20% Karnofsky score with invasive candidiasis. The survival of these patients compared with historical controls matched for similar Karnofsky performance scores and types of fungal infection is shown in Fig 2. A comparison of survival of rhM-CSF-treated patients to historical controls controlling for significant variables affecting survival is shown in Table 4 Comparison was made using
Mantel-Cox statistics; P = ,027.
rhM-CSF-treated patients and historical controls were similar (Table 2) ; however, 2 1 of the rhM-CSF patients received pentoxifylline during the past transplant course compared with none of the historical controls. This was not felt to affect the survival results because administration of pentoxifylline did not affect survival in patients who received rhM-CSF. Variables such as age, sex, maximum dose of rhM-CSF, type of BMT, GVHD, organ of fungal involvement, disease, disease state, use of total body radiation, use of laminar air flow room, and day of rhM-CSF administration also did not affect survival in patients who received rhM-CSF.
DISCUSSION
Overall, patients who received rhM-CSF had better survival then did historical controls or patients reported previ- cor (n = 1) infection (-) who received rhM-CSF compared with 33 historical controls (--) ously.8 However, the difference in overall survival was entirely because of a subset of treated patients with Candida infection and Karnofsky performance scores > 20%. Whether this is related to improved critical care techniques over time or the effect of rhM-CSF on monocyte/macrophage function awaits completion of an ongoing randomized, placebo-controlled trial. The majority of patients who survived long enough to receive the entire course of rhM-CSF did not develop recurrent fungal infection. These data suggest that the improved survival resulted from resolution of fungal disease. Potential beneficial activity of rhM-CSF may be a result of its functional enhancing capacity in monocytes and macrophages. Several in vitro studies have shown activation of monocyte and macrophage function with enhanced fungicidal activity after exposure to rhM-CSF."-I4 Improved survival because of reduced mortality was also observed in Candida-infected mice and rats given rhM-CSF.'*,'' Enhanced function of monocytes occurs within 2 hours of administration of M-CSF in patients with lymphoma.I6 Some effects of M-CSF may also be via indirect mechanisms. rhM-CSF stimulates monocyte production of granulocyte CSF, granulocyte-macrophage (GM) CSF, interleukin-1, tumor necrosis factor-a, and interferon in vivo. These cytokines may further enhance cellular abilities to kill infecting organism~.'~ Determination of monocyte and/or macrophage function and circulating cytokine levels may identify patients likely or unlikely to respond to rhM-CSF or other growth factors." rhGM-CSF may have similar antifungal properties to rhM-CSF,L8,19 whereas rhG-CSF is without affect." Results of this trial further substantiate those of the previously reported data and suggest that rhM-CSF is well tolerated at doses up to 2,000 pg/m2/d. Reduction of the dose by 50% seems to minimize the severity of thrombocytopenia although the effects ofthe lower dose on functional enhancement of monocytes and macrophages may be reduced. Randomized placebo-controlled trials are needed to determine definitively the effect of rhM-CSF on resolution of fungal infection and survival.
